<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00074178</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00000935</org_study_id>
    <secondary_id>5729-2</secondary_id>
    <secondary_id>ONC-99055-L</secondary_id>
    <secondary_id>935</secondary_id>
    <secondary_id>OHSU-5729-2</secondary_id>
    <nct_id>NCT00074178</nct_id>
  </id_info>
  <brief_title>Methotrexate, Cyclophosphamide, and Etoposide Phosphate Given With Osmotic Blood-Brain Barrier Disruption Plus Dexamethasone and Cytarabine in Treating Patients With Primary CNS Lymphoma</brief_title>
  <acronym>Protocol-B</acronym>
  <official_title>Combination Chemotherapy (Methotrexate, Cyclophosphamide, And Etoposide Phosphate) Delivered In Conjunction With Osmotic Blood-Brain Barrier Disruption (BBBD), With Intraventricular Cytarabine +/- Intra-Ocular Chemotherapy, In Patients With Primary Central Nervous System Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OHSU Knight Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>OHSU Knight Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as methotrexate, cyclophosphamide, etoposide&#xD;
      phosphate, dexamethasone, and cytarabine, work in different ways to stop cancer cells from&#xD;
      dividing so they stop growing or die. Osmotic blood-brain barrier disruption uses certain&#xD;
      drugs to open the blood vessels around the brain and allow anticancer substances to be&#xD;
      delivered directly to the brain. Giving methotrexate, cyclophosphamide, and etoposide&#xD;
      phosphate with osmotic blood-brain barrier disruption plus dexamethasone and cytarabine may&#xD;
      kill more cancer cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of giving methotrexate, cyclophosphamide,&#xD;
      and etoposide phosphate with osmotic blood-brain barrier disruption plus dexamethasone and&#xD;
      cytarabine in treating patients who have primary CNS lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the toxicity and efficacy of methotrexate, cyclophosphamide, and etoposide&#xD;
           phosphate administered in conjunction with osmotic blood-brain barrier disruption and&#xD;
           dexamethasone and cytarabine in patients with primary CNS lymphoma.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the ability to recruit an adequate number of patients for this study.&#xD;
&#xD;
        -  Compare progression-free and dementia-free survival with standard measures of overall&#xD;
           survival, progression-free survival, disease-free survival, complete response rate,&#xD;
           cognitive function, and quality of life of patients treated with this regimen.&#xD;
&#xD;
        -  Determine the feasibility of conducting a future phase III study of this treatment&#xD;
           regimen in this patient population.&#xD;
&#xD;
        -  Correlate neuropsychological outcomes with neuroimaging (MRI) outcomes in patients&#xD;
           treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive methotrexate (MTX) intra-arterially over 10 minutes, cyclophosphamide IV&#xD;
      over 10 minutes, and etoposide phosphate IV over 10 minutes on days 1 and 2 in conjunction&#xD;
      with osmotic blood-brain barrier disruption. Patients also receive oral dexamethasone every 6&#xD;
      hours on days 2-15 (followed by a taper) and intraventricular or intrathecal cytarabine on&#xD;
      day 14. Beginning 48 hours after the last dose of MTX, patients receive filgrastim (G-CSF)*&#xD;
      subcutaneously once daily for 7-10 days or until blood counts recover. Treatment repeats&#xD;
      every 4 weeks for 12 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      NOTE: *Alternatively, patients may receive a single dose of pegfilgrastim, administered 24&#xD;
      hours after the completion of chemotherapy&#xD;
&#xD;
      Patients with intraocular lymphoma also receive MTX intravitreally twice weekly until the&#xD;
      vitreous is clear of cells by slit lamp exam and then weekly for 1 month and monthly for 1&#xD;
      year.&#xD;
&#xD;
      Quality of life is assessed at baseline, at 6 months, at the completion of treatment, and&#xD;
      then every 6 months for 2 years and annually thereafter.&#xD;
&#xD;
      Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then&#xD;
      annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 90 patients will be accrued for this study within 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2000</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival as measured by clinical and radiographic response at 5 years after study treatment</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival as measured by clinical and radiographic response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival as measured by clinical and radiographic response until tumor progression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QOL) as measured by EORTC QOL before and after study treatment, every 6 months for 2 years, and then annually</measure>
  </secondary_outcome>
  <enrollment type="Actual">22</enrollment>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pegfilgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide phosphate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed intermediate- or high-grade primary CNS&#xD;
             lymphoma by brain biopsy or cerebrospinal fluid or vitrectomy analysis&#xD;
&#xD;
          -  No more than 90 days since diagnosis&#xD;
&#xD;
          -  No systemic lymphoma NOTE: A new classification scheme for adult non-Hodgkin's&#xD;
             lymphoma has been adopted by PDQ. The terminology of &quot;indolent&quot; or &quot;aggressive&quot;&#xD;
             lymphoma will replace the former terminology of &quot;low&quot;, &quot;intermediate&quot;, or &quot;high&quot; grade&#xD;
             lymphoma. However, this protocol uses the former terminology.&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  16 to 75&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-3 OR&#xD;
&#xD;
          -  Karnofsky 40-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Hematocrit at least 25% (transfusion allowed)&#xD;
&#xD;
          -  WBC at least 2,500/mm^3&#xD;
&#xD;
          -  Absolute granulocyte count at least 1,200/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3 OR at least lower limit of normal (transfusion&#xD;
             independent)&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 times upper limit of normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine clearance at least 30 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  Adequate cardiac function to tolerate general anesthesia&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  Adequate pulmonary function to tolerate general anesthesia&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception for 2 months before and during study&#xD;
             participation&#xD;
&#xD;
          -  No other uncontrolled clinically significant confounding medical condition within the&#xD;
             past 30 days&#xD;
&#xD;
          -  No known allergy to study agents&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)&#xD;
&#xD;
               -  Single-agent methotrexate administered within the past 14 days allowed&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior cranial or spinal radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Prior surgery or biopsy allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward A. Neuwelt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>OHSU Knight Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>December 10, 2003</study_first_submitted>
  <study_first_submitted_qc>December 10, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2003</study_first_posted>
  <last_update_submitted>April 19, 2017</last_update_submitted>
  <last_update_submitted_qc>April 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>OHSU Knight Cancer Institute</investigator_affiliation>
    <investigator_full_name>Edward Neuwelt</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>primary central nervous system lymphoma</keyword>
  <keyword>intraocular lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

